MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents

Méthodes de traitement de la maladie d'alzheimer

Info

Publication number
MA45149A
MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
methods
Prior art date
Application number
MA045149A
Other languages
English (en)
Inventor
Brendon Phillip Boot
Jeffrey Joseph Sevigny
Leslie Lugene Williams
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA45149A publication Critical patent/MA45149A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045149A 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer MA45149A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
MA45149A true MA45149A (fr) 2019-04-10

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045149A MA45149A (fr) 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer

Country Status (12)

Country Link
US (3) US20200308259A1 (fr)
EP (1) EP3464350A1 (fr)
JP (3) JP2019517540A (fr)
KR (2) KR20230165883A (fr)
CN (3) CN114931635A (fr)
AU (2) AU2017276656A1 (fr)
BR (1) BR112018075300A2 (fr)
CA (1) CA3026598A1 (fr)
IL (1) IL263433B2 (fr)
MA (1) MA45149A (fr)
MX (1) MX2018015022A (fr)
WO (1) WO2017211827A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (fr) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Cible thérapeutique et anticorps monoclonaux contre elle pour le diagnostic et le traitement de la maladie d'alzheimer
SG11202110504XA (en) 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
CN114599393A (zh) * 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
EP4351643A4 (fr) * 2021-06-07 2025-08-06 Biogen Ma Inc Méthodes de traitement de la maladie d'alzheimer
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
CA3237165A1 (fr) * 2021-11-19 2023-05-25 Jeng-Horng Her Anticorps bispecifiques ciblant cd137 et leurs utilisations dans l'immunotherapie anticancereuse
CN122175980B (zh) * 2026-05-12 2026-07-17 四川大学华西医院 一种淀粉样蛋白相关影像学异常的磁共振图像随访方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ607881A (en) * 2006-07-14 2014-11-28 Genentech Inc Humanized antibody against amyloid beta
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
KR102308915B1 (ko) * 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
EP2928494A4 (fr) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh Procédé de réduction des plaques amyloïdes cérébrales au moyen d'anticorps anti-ass
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
NZ723884A (en) * 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
KR20230165883A (ko) 2023-12-05
CN114931635A (zh) 2022-08-23
CA3026598A1 (fr) 2017-12-14
AU2017276656A1 (en) 2018-12-13
US20260193332A1 (en) 2026-07-09
EP3464350A1 (fr) 2019-04-10
JP2019517540A (ja) 2019-06-24
KR20190021311A (ko) 2019-03-05
IL263433B2 (en) 2024-03-01
US20220281963A1 (en) 2022-09-08
IL263433B1 (en) 2023-11-01
CN114796481A (zh) 2022-07-29
US20200308259A1 (en) 2020-10-01
JP2022145965A (ja) 2022-10-04
AU2024216442A1 (en) 2024-10-17
BR112018075300A2 (pt) 2019-04-30
WO2017211827A1 (fr) 2017-12-14
MX2018015022A (es) 2019-08-14
JP2025160337A (ja) 2025-10-22
IL263433A (en) 2019-01-31
CN109476730A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3644996A4 (fr) Procédés de traitement de la maladie de huntington
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3019523A4 (fr) Méthodes permettant de traiter la maladie d'alzheimer et la maladie de huntington
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
EP3386520A4 (fr) Méthodes de traitement d'une maladie ou d'un trouble oculaire
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
IL263433A (en) Methods for treating alzheimer's disease
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
EP3454793A4 (fr) Bobines de traitement d'anévrisme
HUE059387T2 (hu) Parkinson-kór kezelése
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn